PHILADELPHIA — Type 1 diabetes (T1D) patients who have developed low blood sugar (hypoglycemia) as a complication of insulin treatments over time are able to regain normal internal recognition of the condition after receiving pancreatic islet cell transplantation, according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania, published online in Diabetes. Severe hypoglycemia—a life-threatening complication of insulin treatment for T1D—can occur when the body’s defense mechanisms against low blood sugar are broken down over a long period of time, causing shakiness, irritability, confusion, lightheadedness, shortness of breath, and even seizures or loss of consciousness.
In this study, led by Michael R. Rickels, MD, MS, associate professor of Medicine and medical director of the Pancreatic Islet Cell Transplant Program at Penn Medicine, T1D patients who were suffering from “hypoglycemia unawareness”—when a patient has low blood sugar, but feels no symptoms—were able to internally recognize the condition and automatically increase their own blood sugar to normal levels six months after undergoing islet cell transplantation. Pancreatic islets are tiny clusters of cells within the pancreas that contain several types of cells, including cells that produce insulin to help the body process sugar.
“The results of this study suggest that islet cell transplantation may be an effective treatment for patients with type 1 diabetes who are experiencing significant hypoglycemic events because their body isn’t able to recognize their low blood sugar levels,” said Rickels. “Currently, islet cell transplantation is considered investigational for type 1 diabetes patients, but this study shows that it has the potential to dramatically improve a patient’s ability to defend against and recognize symptoms of hypoglycemia and eliminate severe hypoglycemic episodes.”
Patients who undergo pancreatic islet cell transplantation receive islets from deceased donors, sometimes through two separate infusions. In this study, 12 patients with hypoglycemia unawareness and frequent severe hypoglycemia events underwent either one or two infusions of islets in order to achieve insulin-independence. The subjects all had approximately 30 years of disease history before the infusion, and their bodies’ ability to recognize hypoglycemia was measured prior to the infusion and at six to seven months afterwards. The results were then compared to a control group. Following the islet cell transplantation, the subjects’ time spent hypoglycemic was nearly abolished. In addition, their bodies were able to appropriately respond to experimental insulin-induced hypoglycemia following transplantation.
“Now that we’ve seen improvement in the protection against hypoglycemia as a result of islet cell transplantation, we’re evaluating the longer term durability of these restored defense mechanisms,” said Rickels. Additional work in the laboratory of Ali Naji, MD, PhD, the J. William White professor of Surgery and co-director of the Type 1 Diabetes Unit for Penn’s Institute for Diabetes, Obesity and Metabolism, is aimed at the development of new immunosuppression medication approaches to reduce the risk for adverse side effects.
The paper’s co-authors, all of whom are from Penn, include Carissa Fuller, CRNP, Cornelia Dalton-Bakes, CCRC, Eileen Markmann, BSN, RN, Maral Palanjian, RN, Kevin Cullison, MD, Janice Tiao, Shiv Kapoor, PhD, Chengyang Liu, MD, Ali Naji, MD, PhD, and Karen L. Teff, PhD.
The study was performed as a project of the Clinical Islet Transplantation Consortium, a collaborative clinical research program headquartered at the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases, and supported by Public Health Services Research Grants U01 DK070430, R01 DK091331, UL1 TR000003, P30 DK19525 and T32 DK007314.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.